Clinical trial · Interventional
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or palliative chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PANVAC™-VF | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years of age who have been vaccinated against smallpox; * Histologically confirmed diagnosis of adenocarcinoma of the pancreas; * Patient has metastatic (Stage IV) disease; * ECOG performance status 0-1; * Failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry. Exclusion Criteria: * Prior or concurrent immunotherapy for cancer; * Radiation therapy within 28 days prior to registration; * Systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration; * Significant cardiovascular abnormalities or diseases; * Known positive for HIV, hepatitis B and/or C; * Evidence of immunodeficiency or immune suppression.
References
Publications (0)
Data not yet available